Recent Advances in the Management of Chronic Hepatitis B Including Suppression of Hepatocellular Carcinoma by Entecavir and Interferon
At present, for adults with chronic hepatitis B virus (HBV) infection, two new analogues, entecavir (ETV) and tenofovir, are recommended as the first-line therapy by the EASL (European Association for the Study of the Liver), AASLD (American Association for the Study of Liver Diseases), and APASL (A...
Gespeichert in:
| Veröffentlicht in: | Oncology 2015-11, Vol.89 (Suppl 2), p.60-69 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 69 |
|---|---|
| container_issue | Suppl 2 |
| container_start_page | 60 |
| container_title | Oncology |
| container_volume | 89 |
| creator | Kim, Soo Ki Kim, Soo Ryang Imoto, Susumu Tohyama, Madoka Otono, Yumi Tamura, Tomoko Kim, Ke Ih Kobayashi, Mana Ohtani, Aya Sugimoto, Kayo Mizuguchi, Aya Hiramatsu, Yukiko Kudo, Masatoshi |
| description | At present, for adults with chronic hepatitis B virus (HBV) infection, two new analogues, entecavir (ETV) and tenofovir, are recommended as the first-line therapy by the EASL (European Association for the Study of the Liver), AASLD (American Association for the Study of Liver Diseases), and APASL (Asian Pacific Association for the Study of the Liver) guidelines. The use of pegylated interferon-α (PEG IFN-α) is recommended as the first-line therapy instead of standard IFN-α according to the above 3 guidelines. In this paper, the aim was to assess: (1) the long-term efficacy and safety as well as the resistance to ETV and tenofovir disoproxil fumarate (TDF); (2) the efficacy of PEG IFN-α; (3) the role of combination therapy with IFN plus two analogues, such as lamivudine and ETV; (4) the efficacy and safety of two analogues with cirrhosis, and (5) suppression of hepatocellular carcinoma (HCC) by ETV and IFN treatment. The results are as follows: (1) both ETV and TDF showed long-term efficacy and safety; (2) PEG IFN-α resulted in a greater decline in HBV DNA levels and a higher rate of HBeAg seroconversion; (3) combination therapy with IFN plus two analogues did not elevate the rate of sustained responses; (4) both ETV and TDF showed efficacy and safety with cirrhosis (ETV especially displayed efficacy and safety with decompensated cirrhosis), and (5) suppression of HCC was observed by ETV and IFN. |
| doi_str_mv | 10.1159/000440633 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1785242370</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A637396654</galeid><sourcerecordid>A637396654</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-9eee8a191f564748c71e6005e6f3dfe150b5956b77c73e98d8f253a89d13c4ee3</originalsourceid><addsrcrecordid>eNqN0stu1DAUBmBzE52WLtgjZAkJwSJgx_flMCq0UhESl3XkcU5mUhI72E6lvgDPjYeZzoIVKy_O59_28UHoOSXvKBXmPSGEcyIZe4DOjdKMUU2ErI16iBaU16wiNasfodP7gpaP0YIQRqqaU36CTlO6KRlKcPkUndRSaE6YWqDfX8GBz3jZ3lrvIOHe47wF_Nl6u4FxVwodXm1j8L3DlzDZ3Oc-4Q_4yrthbnu_wd_maYqQUh_8Dv9FwcEwzIONeGWj630YLV7f4QufwdnbPmLr2xKRIXZQsp-hJ50dEpwf1jP04-PF99Vldf3l09VqeV05ZnSuDABoSw3thOSKa6coSEIEyI61HVBB1sIIuVbKKQZGt7qrBbPatJQ5DsDO0Jt97hTDrxlSbsY-7a5qPYQ5NVRpUZd2KvIflMnSWlHTQl_9Q2_CHH15SFGCU8E4E0W93quNHaDZgh3yNoVhzqVvqVlKppiRUvAC3-6hiyGlCF0zxX608a6hpNlNQ3OchmJfHo6e1yO0R3n_wwW82IOfNm4gHsFh_x9QVbH6</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1754153435</pqid></control><display><type>article</type><title>Recent Advances in the Management of Chronic Hepatitis B Including Suppression of Hepatocellular Carcinoma by Entecavir and Interferon</title><source>MEDLINE</source><source>Karger Journals Complete</source><creator>Kim, Soo Ki ; Kim, Soo Ryang ; Imoto, Susumu ; Tohyama, Madoka ; Otono, Yumi ; Tamura, Tomoko ; Kim, Ke Ih ; Kobayashi, Mana ; Ohtani, Aya ; Sugimoto, Kayo ; Mizuguchi, Aya ; Hiramatsu, Yukiko ; Kudo, Masatoshi</creator><creatorcontrib>Kim, Soo Ki ; Kim, Soo Ryang ; Imoto, Susumu ; Tohyama, Madoka ; Otono, Yumi ; Tamura, Tomoko ; Kim, Ke Ih ; Kobayashi, Mana ; Ohtani, Aya ; Sugimoto, Kayo ; Mizuguchi, Aya ; Hiramatsu, Yukiko ; Kudo, Masatoshi</creatorcontrib><description>At present, for adults with chronic hepatitis B virus (HBV) infection, two new analogues, entecavir (ETV) and tenofovir, are recommended as the first-line therapy by the EASL (European Association for the Study of the Liver), AASLD (American Association for the Study of Liver Diseases), and APASL (Asian Pacific Association for the Study of the Liver) guidelines. The use of pegylated interferon-α (PEG IFN-α) is recommended as the first-line therapy instead of standard IFN-α according to the above 3 guidelines. In this paper, the aim was to assess: (1) the long-term efficacy and safety as well as the resistance to ETV and tenofovir disoproxil fumarate (TDF); (2) the efficacy of PEG IFN-α; (3) the role of combination therapy with IFN plus two analogues, such as lamivudine and ETV; (4) the efficacy and safety of two analogues with cirrhosis, and (5) suppression of hepatocellular carcinoma (HCC) by ETV and IFN treatment. The results are as follows: (1) both ETV and TDF showed long-term efficacy and safety; (2) PEG IFN-α resulted in a greater decline in HBV DNA levels and a higher rate of HBeAg seroconversion; (3) combination therapy with IFN plus two analogues did not elevate the rate of sustained responses; (4) both ETV and TDF showed efficacy and safety with cirrhosis (ETV especially displayed efficacy and safety with decompensated cirrhosis), and (5) suppression of HCC was observed by ETV and IFN.</description><identifier>ISSN: 0030-2414</identifier><identifier>ISBN: 3318056286</identifier><identifier>ISBN: 9783318056280</identifier><identifier>EISSN: 1423-0232</identifier><identifier>EISBN: 9783318056297</identifier><identifier>EISBN: 3318056294</identifier><identifier>DOI: 10.1159/000440633</identifier><identifier>PMID: 26584037</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Adult ; Antiviral Agents - therapeutic use ; Cancer therapies ; Carcinoma, Hepatocellular - epidemiology ; Carcinoma, Hepatocellular - prevention & control ; Carcinoma, Hepatocellular - virology ; Clinical Trials as Topic ; Complications and side effects ; Disease Management ; Drug therapy ; Drug Therapy, Combination ; Entecavir ; Guanine - analogs & derivatives ; Guanine - therapeutic use ; Hepacivirus - drug effects ; Hepacivirus - genetics ; Hepatitis ; Hepatitis B ; Hepatitis B virus ; Hepatitis C, Chronic - blood ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - virology ; Hepatocellular carcinoma ; Humans ; Interferon ; Interferon-alpha - therapeutic use ; Japan - epidemiology ; Liver cancer ; Liver Neoplasms - epidemiology ; Liver Neoplasms - prevention & control ; Liver Neoplasms - virology ; Oncology ; Patient outcomes ; Practice Guidelines as Topic ; Prevention ; Prognosis ; Review</subject><ispartof>Oncology, 2015-11, Vol.89 (Suppl 2), p.60-69</ispartof><rights>2015 S. Karger AG, Basel</rights><rights>2015 S. Karger AG, Basel.</rights><rights>COPYRIGHT 2015 S. Karger AG</rights><rights>Copyright S. Karger AG Nov 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-9eee8a191f564748c71e6005e6f3dfe150b5956b77c73e98d8f253a89d13c4ee3</citedby><cites>FETCH-LOGICAL-c398t-9eee8a191f564748c71e6005e6f3dfe150b5956b77c73e98d8f253a89d13c4ee3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26584037$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Soo Ki</creatorcontrib><creatorcontrib>Kim, Soo Ryang</creatorcontrib><creatorcontrib>Imoto, Susumu</creatorcontrib><creatorcontrib>Tohyama, Madoka</creatorcontrib><creatorcontrib>Otono, Yumi</creatorcontrib><creatorcontrib>Tamura, Tomoko</creatorcontrib><creatorcontrib>Kim, Ke Ih</creatorcontrib><creatorcontrib>Kobayashi, Mana</creatorcontrib><creatorcontrib>Ohtani, Aya</creatorcontrib><creatorcontrib>Sugimoto, Kayo</creatorcontrib><creatorcontrib>Mizuguchi, Aya</creatorcontrib><creatorcontrib>Hiramatsu, Yukiko</creatorcontrib><creatorcontrib>Kudo, Masatoshi</creatorcontrib><title>Recent Advances in the Management of Chronic Hepatitis B Including Suppression of Hepatocellular Carcinoma by Entecavir and Interferon</title><title>Oncology</title><addtitle>Oncology</addtitle><description>At present, for adults with chronic hepatitis B virus (HBV) infection, two new analogues, entecavir (ETV) and tenofovir, are recommended as the first-line therapy by the EASL (European Association for the Study of the Liver), AASLD (American Association for the Study of Liver Diseases), and APASL (Asian Pacific Association for the Study of the Liver) guidelines. The use of pegylated interferon-α (PEG IFN-α) is recommended as the first-line therapy instead of standard IFN-α according to the above 3 guidelines. In this paper, the aim was to assess: (1) the long-term efficacy and safety as well as the resistance to ETV and tenofovir disoproxil fumarate (TDF); (2) the efficacy of PEG IFN-α; (3) the role of combination therapy with IFN plus two analogues, such as lamivudine and ETV; (4) the efficacy and safety of two analogues with cirrhosis, and (5) suppression of hepatocellular carcinoma (HCC) by ETV and IFN treatment. The results are as follows: (1) both ETV and TDF showed long-term efficacy and safety; (2) PEG IFN-α resulted in a greater decline in HBV DNA levels and a higher rate of HBeAg seroconversion; (3) combination therapy with IFN plus two analogues did not elevate the rate of sustained responses; (4) both ETV and TDF showed efficacy and safety with cirrhosis (ETV especially displayed efficacy and safety with decompensated cirrhosis), and (5) suppression of HCC was observed by ETV and IFN.</description><subject>Adult</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Cancer therapies</subject><subject>Carcinoma, Hepatocellular - epidemiology</subject><subject>Carcinoma, Hepatocellular - prevention & control</subject><subject>Carcinoma, Hepatocellular - virology</subject><subject>Clinical Trials as Topic</subject><subject>Complications and side effects</subject><subject>Disease Management</subject><subject>Drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Entecavir</subject><subject>Guanine - analogs & derivatives</subject><subject>Guanine - therapeutic use</subject><subject>Hepacivirus - drug effects</subject><subject>Hepacivirus - genetics</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis B virus</subject><subject>Hepatitis C, Chronic - blood</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - virology</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Interferon</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Japan - epidemiology</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - epidemiology</subject><subject>Liver Neoplasms - prevention & control</subject><subject>Liver Neoplasms - virology</subject><subject>Oncology</subject><subject>Patient outcomes</subject><subject>Practice Guidelines as Topic</subject><subject>Prevention</subject><subject>Prognosis</subject><subject>Review</subject><issn>0030-2414</issn><issn>1423-0232</issn><isbn>3318056286</isbn><isbn>9783318056280</isbn><isbn>9783318056297</isbn><isbn>3318056294</isbn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqN0stu1DAUBmBzE52WLtgjZAkJwSJgx_flMCq0UhESl3XkcU5mUhI72E6lvgDPjYeZzoIVKy_O59_28UHoOSXvKBXmPSGEcyIZe4DOjdKMUU2ErI16iBaU16wiNasfodP7gpaP0YIQRqqaU36CTlO6KRlKcPkUndRSaE6YWqDfX8GBz3jZ3lrvIOHe47wF_Nl6u4FxVwodXm1j8L3DlzDZ3Oc-4Q_4yrthbnu_wd_maYqQUh_8Dv9FwcEwzIONeGWj630YLV7f4QufwdnbPmLr2xKRIXZQsp-hJ50dEpwf1jP04-PF99Vldf3l09VqeV05ZnSuDABoSw3thOSKa6coSEIEyI61HVBB1sIIuVbKKQZGt7qrBbPatJQ5DsDO0Jt97hTDrxlSbsY-7a5qPYQ5NVRpUZd2KvIflMnSWlHTQl_9Q2_CHH15SFGCU8E4E0W93quNHaDZgh3yNoVhzqVvqVlKppiRUvAC3-6hiyGlCF0zxX608a6hpNlNQ3OchmJfHo6e1yO0R3n_wwW82IOfNm4gHsFh_x9QVbH6</recordid><startdate>20151101</startdate><enddate>20151101</enddate><creator>Kim, Soo Ki</creator><creator>Kim, Soo Ryang</creator><creator>Imoto, Susumu</creator><creator>Tohyama, Madoka</creator><creator>Otono, Yumi</creator><creator>Tamura, Tomoko</creator><creator>Kim, Ke Ih</creator><creator>Kobayashi, Mana</creator><creator>Ohtani, Aya</creator><creator>Sugimoto, Kayo</creator><creator>Mizuguchi, Aya</creator><creator>Hiramatsu, Yukiko</creator><creator>Kudo, Masatoshi</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope><scope>7U9</scope></search><sort><creationdate>20151101</creationdate><title>Recent Advances in the Management of Chronic Hepatitis B Including Suppression of Hepatocellular Carcinoma by Entecavir and Interferon</title><author>Kim, Soo Ki ; Kim, Soo Ryang ; Imoto, Susumu ; Tohyama, Madoka ; Otono, Yumi ; Tamura, Tomoko ; Kim, Ke Ih ; Kobayashi, Mana ; Ohtani, Aya ; Sugimoto, Kayo ; Mizuguchi, Aya ; Hiramatsu, Yukiko ; Kudo, Masatoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-9eee8a191f564748c71e6005e6f3dfe150b5956b77c73e98d8f253a89d13c4ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Cancer therapies</topic><topic>Carcinoma, Hepatocellular - epidemiology</topic><topic>Carcinoma, Hepatocellular - prevention & control</topic><topic>Carcinoma, Hepatocellular - virology</topic><topic>Clinical Trials as Topic</topic><topic>Complications and side effects</topic><topic>Disease Management</topic><topic>Drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Entecavir</topic><topic>Guanine - analogs & derivatives</topic><topic>Guanine - therapeutic use</topic><topic>Hepacivirus - drug effects</topic><topic>Hepacivirus - genetics</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis B virus</topic><topic>Hepatitis C, Chronic - blood</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - virology</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Interferon</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Japan - epidemiology</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - epidemiology</topic><topic>Liver Neoplasms - prevention & control</topic><topic>Liver Neoplasms - virology</topic><topic>Oncology</topic><topic>Patient outcomes</topic><topic>Practice Guidelines as Topic</topic><topic>Prevention</topic><topic>Prognosis</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Soo Ki</creatorcontrib><creatorcontrib>Kim, Soo Ryang</creatorcontrib><creatorcontrib>Imoto, Susumu</creatorcontrib><creatorcontrib>Tohyama, Madoka</creatorcontrib><creatorcontrib>Otono, Yumi</creatorcontrib><creatorcontrib>Tamura, Tomoko</creatorcontrib><creatorcontrib>Kim, Ke Ih</creatorcontrib><creatorcontrib>Kobayashi, Mana</creatorcontrib><creatorcontrib>Ohtani, Aya</creatorcontrib><creatorcontrib>Sugimoto, Kayo</creatorcontrib><creatorcontrib>Mizuguchi, Aya</creatorcontrib><creatorcontrib>Hiramatsu, Yukiko</creatorcontrib><creatorcontrib>Kudo, Masatoshi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Virology and AIDS Abstracts</collection><jtitle>Oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Soo Ki</au><au>Kim, Soo Ryang</au><au>Imoto, Susumu</au><au>Tohyama, Madoka</au><au>Otono, Yumi</au><au>Tamura, Tomoko</au><au>Kim, Ke Ih</au><au>Kobayashi, Mana</au><au>Ohtani, Aya</au><au>Sugimoto, Kayo</au><au>Mizuguchi, Aya</au><au>Hiramatsu, Yukiko</au><au>Kudo, Masatoshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recent Advances in the Management of Chronic Hepatitis B Including Suppression of Hepatocellular Carcinoma by Entecavir and Interferon</atitle><jtitle>Oncology</jtitle><addtitle>Oncology</addtitle><date>2015-11-01</date><risdate>2015</risdate><volume>89</volume><issue>Suppl 2</issue><spage>60</spage><epage>69</epage><pages>60-69</pages><issn>0030-2414</issn><eissn>1423-0232</eissn><isbn>3318056286</isbn><isbn>9783318056280</isbn><eisbn>9783318056297</eisbn><eisbn>3318056294</eisbn><abstract>At present, for adults with chronic hepatitis B virus (HBV) infection, two new analogues, entecavir (ETV) and tenofovir, are recommended as the first-line therapy by the EASL (European Association for the Study of the Liver), AASLD (American Association for the Study of Liver Diseases), and APASL (Asian Pacific Association for the Study of the Liver) guidelines. The use of pegylated interferon-α (PEG IFN-α) is recommended as the first-line therapy instead of standard IFN-α according to the above 3 guidelines. In this paper, the aim was to assess: (1) the long-term efficacy and safety as well as the resistance to ETV and tenofovir disoproxil fumarate (TDF); (2) the efficacy of PEG IFN-α; (3) the role of combination therapy with IFN plus two analogues, such as lamivudine and ETV; (4) the efficacy and safety of two analogues with cirrhosis, and (5) suppression of hepatocellular carcinoma (HCC) by ETV and IFN treatment. The results are as follows: (1) both ETV and TDF showed long-term efficacy and safety; (2) PEG IFN-α resulted in a greater decline in HBV DNA levels and a higher rate of HBeAg seroconversion; (3) combination therapy with IFN plus two analogues did not elevate the rate of sustained responses; (4) both ETV and TDF showed efficacy and safety with cirrhosis (ETV especially displayed efficacy and safety with decompensated cirrhosis), and (5) suppression of HCC was observed by ETV and IFN.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>26584037</pmid><doi>10.1159/000440633</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0030-2414 |
| ispartof | Oncology, 2015-11, Vol.89 (Suppl 2), p.60-69 |
| issn | 0030-2414 1423-0232 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1785242370 |
| source | MEDLINE; Karger Journals Complete |
| subjects | Adult Antiviral Agents - therapeutic use Cancer therapies Carcinoma, Hepatocellular - epidemiology Carcinoma, Hepatocellular - prevention & control Carcinoma, Hepatocellular - virology Clinical Trials as Topic Complications and side effects Disease Management Drug therapy Drug Therapy, Combination Entecavir Guanine - analogs & derivatives Guanine - therapeutic use Hepacivirus - drug effects Hepacivirus - genetics Hepatitis Hepatitis B Hepatitis B virus Hepatitis C, Chronic - blood Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - virology Hepatocellular carcinoma Humans Interferon Interferon-alpha - therapeutic use Japan - epidemiology Liver cancer Liver Neoplasms - epidemiology Liver Neoplasms - prevention & control Liver Neoplasms - virology Oncology Patient outcomes Practice Guidelines as Topic Prevention Prognosis Review |
| title | Recent Advances in the Management of Chronic Hepatitis B Including Suppression of Hepatocellular Carcinoma by Entecavir and Interferon |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T00%3A59%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recent%20Advances%20in%20the%20Management%20of%20Chronic%20Hepatitis%20B%20Including%20Suppression%20of%20Hepatocellular%20Carcinoma%20by%20Entecavir%20and%20Interferon&rft.jtitle=Oncology&rft.au=Kim,%20Soo%20Ki&rft.date=2015-11-01&rft.volume=89&rft.issue=Suppl%202&rft.spage=60&rft.epage=69&rft.pages=60-69&rft.issn=0030-2414&rft.eissn=1423-0232&rft.isbn=3318056286&rft.isbn_list=9783318056280&rft_id=info:doi/10.1159/000440633&rft_dat=%3Cgale_proqu%3EA637396654%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&rft.eisbn=9783318056297&rft.eisbn_list=3318056294&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1754153435&rft_id=info:pmid/26584037&rft_galeid=A637396654&rfr_iscdi=true |